These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 18032664)

  • 1. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice.
    Stack EC; Dedeoglu A; Smith KM; Cormier K; Kubilus JK; Bogdanov M; Matson WR; Yang L; Jenkins BG; Luthi-Carter R; Kowall NW; Hersch SM; Beal MF; Ferrante RJ
    J Neurosci; 2007 Nov; 27(47):12908-15. PubMed ID: 18032664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease.
    Samadi P; Boutet A; Rymar VV; Rawal K; Maheux J; Kvann JC; Tomaszewski M; Beaubien F; Cloutier JF; Levesque D; Sadikot AF
    Genes Brain Behav; 2013 Feb; 12(1):108-24. PubMed ID: 23006318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons.
    Picconi B; Passino E; Sgobio C; Bonsi P; Barone I; Ghiglieri V; Pisani A; Bernardi G; Ammassari-Teule M; Calabresi P
    Neurobiol Dis; 2006 Apr; 22(1):143-52. PubMed ID: 16326108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease.
    Parievsky A; Moore C; Kamdjou T; Cepeda C; Meshul CK; Levine MS
    Neurobiol Dis; 2017 Dec; 108():29-44. PubMed ID: 28757327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased calbindin-D28k immunoreactivity in striatal projection neurons of R6/2 Huntington's disease transgenic mice.
    Sun Z; Wang HB; Deng YP; Lei WL; Xie JP; Meade CA; Del Mar N; Goldowitz D; Reiner A
    Neurobiol Dis; 2005 Dec; 20(3):907-17. PubMed ID: 15990326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
    Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
    J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.
    Milnerwood AJ; Raymond LA
    J Physiol; 2007 Dec; 585(Pt 3):817-31. PubMed ID: 17947312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice.
    Lee J; Kosaras B; Del Signore SJ; Cormier K; McKee A; Ratan RR; Kowall NW; Ryu H
    Acta Neuropathol; 2011 Apr; 121(4):487-98. PubMed ID: 21161248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration.
    Strand AD; Baquet ZC; Aragaki AK; Holmans P; Yang L; Cleren C; Beal MF; Jones L; Kooperberg C; Olson JM; Jones KR
    J Neurosci; 2007 Oct; 27(43):11758-68. PubMed ID: 17959817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington's disease.
    Boussicault L; Alves S; Lamazière A; Planques A; Heck N; Moumné L; Despres G; Bolte S; Hu A; Pagès C; Galvan L; Piguet F; Aubourg P; Cartier N; Caboche J; Betuing S
    Brain; 2016 Mar; 139(Pt 3):953-70. PubMed ID: 26912634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.
    Reiner A; Lafferty DC; Wang HB; Del Mar N; Deng YP
    Neurobiol Dis; 2012 Jul; 47(1):75-91. PubMed ID: 22472187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease.
    Sepers MD; Raymond LA
    Drug Discov Today; 2014 Jul; 19(7):990-6. PubMed ID: 24603212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impaired development of cortico-striatal synaptic connectivity in a cell culture model of Huntington's disease.
    Buren C; Parsons MP; Smith-Dijak A; Raymond LA
    Neurobiol Dis; 2016 Mar; 87():80-90. PubMed ID: 26711622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAK-063, a Novel Phosphodiesterase 10A Inhibitor, Protects from Striatal Neurodegeneration and Ameliorates Behavioral Deficits in the R6/2 Mouse Model of Huntington's Disease.
    Harada A; Suzuki K; Kimura H
    J Pharmacol Exp Ther; 2017 Jan; 360(1):75-83. PubMed ID: 27811172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
    Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
    Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine.
    Petersén A; Hansson O; Puschban Z; Sapp E; Romero N; Castilho RF; Sulzer D; Rice M; DiFiglia M; Przedborski S; Brundin P
    Eur J Neurosci; 2001 Nov; 14(9):1425-35. PubMed ID: 11722604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional behavioral modulation of corticostriatal communication in the R6/2 mouse model of Huntington's disease.
    Hong SL; Cossyleon D; Hussain WA; Walker LJ; Barton SJ; Rebec GV
    PLoS One; 2012; 7(10):e47026. PubMed ID: 23056565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal vulnerability in Huntington's disease.
    Fusco FR; Chen Q; Lamoreaux WJ; Figueredo-Cardenas G; Jiao Y; Coffman JA; Surmeier DJ; Honig MG; Carlock LR; Reiner A
    J Neurosci; 1999 Feb; 19(4):1189-202. PubMed ID: 9952397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.